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Abstract 
Background: This study aims to assess the cost-effectiveness of a routine 
universal antenatal hepatitis C virus (HCV) screening programme at a London  
centre. 
Methods: Ten years’ retrospective antenatal screening and outcome data 
informed a cost-effectiveness analysis using the previously validated 
MONARCH model. The cost and quality-of-life outcomes associated with the 
screening and treatment of newly identified hepatitis C cases were used to 
generate cost-effectiveness estimates for the screening programme.  
Results: A total of 35,355 women were screened between 1st November 
2003 and 1st March 2013; 136 women (0.38%) were found to be HCV 
antibody positive. Of 78 (0.22%) viraemic cases, 44 (0.12%) were newly 
diagnosed. In addition, the screening programme identified three (6.8%)  
vertical transmissions in children of newly diagnosed mothers. Of 16 newly 
diagnosed mothers biopsied, all were in the F0-F2 METAVIR disease stages,  
and 50% had HCV genotype 1. Postnatal treatment with pegylated interferon  
and ribavirin was initiated in 19 women, with 14 (74%) achieving sustained  
virologic response. The total cost of screening and confirmation of diagnoses  
was estimated to be £240,641. This translates to £5,469 per newly diagnosed  
individual. The incremental cost-effectiveness ratio of this screening and  
treatment strategy was £2,400 per QALY gained. Treatment with newer direct  
acting antiviral regimens would have a projected cost of £9,139 per QALY 
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gained, well below the £20,000-30,000/QALY gained willingness-to-pay 
threshold applied by policy advisory bodies.  
Conclusions: This study demonstrates that an antenatal screening and 
treatment programme is feasible and effective, at a cost considered 
acceptable. 
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Introduction 
Hepatitis C virus (HCV) is a blood borne virus with a chronic course in most 
infected individuals. It is usually asymptomatic in the early years, but 
persistent infection can lead to end-stage liver disease (ESLD) and 
hepatocellular carcinoma (HCC) [1]. In the UK, both hospital admissions and 
deaths from HCV-related ESLD and HCC are continuing to rise, and the 
number of transplants indicated due to HCV-related cirrhosis has more than  
quadrupled between 1996 and 2013 [2]. Previously published European 
antenatal data suggest an HCV prevalence of up to 0.6% in this population 
[3][4]. 
It is estimated that at least 40% of cases remain undiagnosed in the UK [2]. In 
2012, birth cohort screening for HCV was recommended by the Centers for 
Disease Control and Prevention (CDC) [5]; however, outside the US,  
screening for HCV is generally only undertaken in high-risk populations. Risk 
based screening may not be effective for three main reasons: firstly, in the 
primary care setting, HCV risk factors are often not fully explored [6][7]; 
secondly, patients do not always report transient behaviours (e.g. injecting 
drug use) that occurred years or decades ago; thirdly, many acquire infection 
iatrogenically in their country of origin and are unaware of exposure risk. 
Other strategies for HCV case finding are therefore becoming increasingly 
pertinent, especially given the recent advances in treatments with the 
introduction of new generation direct acting antivirals (DAAs). Antenatal 
screening for several infectious diseases, including HIV and hepatitis B virus 
(HBV), is performed routinely in many countries including the UK [8]. This is 
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 commonly motivated by the risk of perinatal transmission; this is estimated at 
6% amongst HCV patients [9][10]. However, in the absence of interventions 
available to prevent HCV transmission, routine screening for HCV in 
pregnancy has not been recommended in most countries [11]. Successful 
identification and treatment of HCV-infected individuals is associated with 
improved long-term health, through the avoidance of ESLD, and increased life 
expectancy [12][13]. 
Previous studies have shown benefit in the adoption of a routine antenatal  
screening programme for HCV over risk based testing strategies [3][14]. 
These studies demonstrate that up to 75% of newly diagnosed mothers have  
no reported “high risk” behaviour. Whilst many of these women were born in 
countries with a higher prevalence and risk of infection, screening of migrants 
would potentially be stigmatising. Women screened and diagnosed with HCV 
during the antenatal period are generally healthy and motivated, with high 
rates of attendance to follow-up observed [3]. Given that testing for HCV 
antibodies can be carried out using the same laboratory samples taken for 
routine antenatal virology screening for HIV and HBV, minimal additional 
resource use is required. The costs of diagnostic confirmation and the 
treatment of newly identified patients pose potentially significant costs, but 
these may be offset against the potential future costs of late diagnosis and the 
treatment of complications, should these women be diagnosed only when the 
disease has progressed. 
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 This study aims to evaluate the cost-effectiveness of routine screening for 
HCV antibodies in the antenatal population of a London hospital, based on 
data from a ten-year screening programme, using a previously published and 
validated simulation model of HCV. 
Methods 
Screening and treatment 
Between 1st November 2003 and 1st March 2013, all pregnant women 
attending the antenatal clinics at St Mary’s Hospital, Imperial College 
Healthcare NHS Trust, London for their “booking in” visit were offered HCV 
antibody testing as part of their screening. All positive results were directly 
reported from the virology lab to a specialist midwifery team trained in the 
management of patients with viral hepatitis. All mothers in which HCV 
antibodies were identified were referred to a named consultant hepatologist 
working closely with the antenatal team. Mothers with initial undetectable viral 
load results had a further viral load assessment after the pregnancy to confirm 
spontaneous resolver status, before being discharged from follow-up. Mothers 
with identified viraemia were counselled in the antenatal hepatology clinic and 
reviewed in a family clinic following delivery, with their child, by the same 
hepatologist and a paediatric consultant with specialist interest in infectious 
diseases. All children of infected mothers were tested serologically for HCV at 
15 months. These mothers were then offered regular hepatology follow-up 
and worked up for treatment per standard practice. 
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 Antenatal and medical records were reviewed to evaluate the service 
provided to these women over the last ten years and their outcomes. 
Individual patient data were anonymised. Data were managed using REDCap 
electronic data capture tools [15]. Information recorded included patient 
demographics, antenatal data, maternal HCV status and their risk factors, 
dates of hepatology appointments, outcomes of work up and, if relevant, 
treatment records and outcomes. 
Cost-effectiveness model 
The MONARCH (MOdelling the NAtural histoRy and Cost effectiveness of 
Hepatitis C) model is a previously published and validated HCV disease 
progression and cost-effectiveness model designed to progress a cohort of 
subjects in annual cycles through METAVIR fibrosis stages and potentially to 
ESLD complications and death [16][17]. Patients in METAVIR fibrosis stages  
F0–F4 incur an annual probability of all-cause mortality [18], whilst patients  
suffering from ESLD complications incur disease-specific mortality rates. 
Figure 1 shows the model flow diagram and Table S1 (supplementary data) 
reports the transition rates applied in the model. Disease progression is  
modelled over a lifetime assuming a maximum age of 100 years. Total costs,  
quality-adjusted life-years (QALYs), and numbers of predicted ESLD  
complications and deaths are estimated over the simulated period.  
Fibrosis stage transition probabilities were informed by characteristics of the  
screened population with respect to age, sex, HCV genotype and source of 
infection (Table S1). Initially, patients’ disease stage was reported as either 
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 mild, moderate or severe. To inform the initial distribution of patients across 
fibrosis stages, it was assumed that mild and moderate disease corresponded  
to fibrosis stages F0–F1 and F2–F3, respectively.  
The outcomes of the screening programme were used as the basis of a cost-
effectiveness analysis using the MONARCH model. The additional costs of 
screening were compared to the benefits of identifying new cases and the  
opportunity for treating them, in terms of future quality of life, survival and cost  
implications of long-term HCV complications. The results of modelling were  
used to determine an upper threshold for the cost of screening. The UK  
advisory body, the National Institute of Health and Care Excellence (NICE),  
considers an intervention cost-effective at a threshold of £20,000 to £30,000  
per QALY gained [19]; in the US, the threshold is $50,000 per QALY gained  
[20], and a previous European evaluation of an antenatal HCV screening  
programme applied a threshold of €20,000 to €50,000 [21].  
A healthcare payer perspective was taken and only direct medical costs 
considered. Patient and societal costs, such as increased productivity among 
working adults, were not included. HCV-specific treatment and monitoring 
costs were derived from weekly estimated costs, accommodating duration of 
treatment by HCV genotype. Testing costs were based on cost tariffs at 
Imperial College Healthcare NHS Trust, as demonstrated in Table S2 
(supplemental data). Costs associated with the screening programme  
included the costs of identifying patients through the use of both HCV 
antibody and confirmatory testing amongst all patients; those subsequently 
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 identified as having HCV antibodies underwent RNA, genotype and baseline 
liver screening. Costs associated with liver biopsy were applied to the patients 
that underwent the procedure, whilst patients that were treated incurred  
antiviral therapy-related costs. All costs and health utility estimates (measured 
as QALYs), presented in Table 1, are independent of age and were 
discounted annually at a rate of 3.5%, to reflect their present value. All costs 
were inflated to 2013 values using the Health and Social Care index [22].  
In the base case, the identification and treatment of patients was modelled as 
observed in the women in our study centre treated with pegylated-interferon  
alpha and ribavirin (IFN/RBV) only. It was assumed that patients infected with  
HCV genotypes 1 and 4 received 48 weeks of treatment, and those with HCV  
genotypes 2 and 3 received 24 weeks of therapy. Conservative assumptions 
around drug cost were made; it was assumed no patients ended treatment 
early due to discontinuation or extended rapid virologic response (eRVR). Any 
bias introduced by this assumption would be against the screening strategy. 
Amongst all treated patients, there was no evidence of significant anaemia or 
dose reduction and no blood or platelet transfusions; as such, the costs of 
treating any adverse events were not modelled. Therapy-specific disutility was  
applied to patients whilst receiving treatment, upon completion of treatment no  
further disutility was incurred.  
Two additional scenarios were modelled relating to the introduction of new 
generation DAAs: as either the initial treatment option or as subsequent 
treatment for patients failing to achieve SVR with IFN/RBV; to illustrate this, a 
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treatment success rate (SVR) of 95% for 12 weeks of sofosbuvir triple therapy 
(SOF + IFN/RBV) was applied across all genotypes and fibrosis stages, 
estimated from results of recent phase 3 trials [23][24]. In these additional 
scenarios, the identification of patients for treatment was modelled as 
observed in the study centre. 
Sensitivity analysis 
A series of sensitivity analyses (SA) were conducted, to evaluate the impact 
of uncertainty in the following areas on modelled base case results: 
1) (a) Increasing and (b) decreasing the age at diagnosis by five years. 
2) Adjusting SVR rates associated with IFN/RBV to reflect the consensus 
literature; i.e., 52% in HCV genotype 1 patients [25], 75% in HCV 
genotype 2 patients [26], 75% in HCV genotype 3 patients [26], and 
48% in HCV genotype 4 patients [27]. 
3) Treatment of all newly diagnosed patients. 
4) HCV prevalence amongst the screened population of (a) 0.1% and (b) 
0.6%. 
Results 
Results of the screening and treatment programme 
During the ten-year period evaluated, a total of 35,355 women underwent 
antenatal HCV screening at St Mary’s Hospital. A total of 136 (0.38%) HCV 
antibody positive results were confirmed (figure 2). Overall, 44 women  
(0.12%) were newly diagnosed with chronic HCV. Of the remaining 92 women  
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with positive HCV antibody results, 34 had received prior diagnosis and 58  
had sequential negative HCV viral loads, indicating spontaneous clearance of 
the virus.  
Of the 44 newly diagnosed women, the majority were HCV genotypes 1 and 3 
(figure 2), with a median age of 33 years (range 23–46) at diagnosis. None 
were co-infected with either HIV or HBV. Subsequently, a total of 19 women  
underwent treatment for HCV with IFN/RBV, of which 14 (74%) achieved  
SVR. Three additional women were treated and achieved SVR, one genotype 
1 with IFN/RBV and boceprevir and two genotype 4 patients with DAAs as 
part of a clinical trial.  
Of the 44 newly diagnosed women, 14 were born in the UK, 14 in Eastern  
Europe, 3 in Western Europe, 4 in Africa and 9 in Asia. The likely source of 
HCV infection was identified as blood transfusion for one mother, whilst 11 out  
of the 44 mothers had a prior history of injecting drug use. Of these 11  
women, one spontaneously cleared the virus the year after diagnosis and two  
underwent treatment, with one successful SVR. On review of the reasons for 
not undertaking treatment, eight mothers did not attend clinic follow-up due to  
complex social factors.  
Five (11%) children born to mothers newly diagnosed with HCV had evidence 
of HCV antibodies when tested. One child had a weak antibody response but 
never had detectable HCV RNA, and a second child who had a viral load of 7  
13 
x106 IU/mL at the age of 4 months had spontaneously cleared the virus by the  
  
5
 
2 
age of 12 months. Three children (6.8%) are under active follow-up with  
vertically acquired HCV, all with HCV genotype 3a, one of which is  
undergoing treatment with IFN/RBV at the time of writing. At least ten other 
cases were also identified as result of contact tracing as a consequence of 
mothers being diagnosed.  
Cost-effectiveness results 
The total cost of screening and confirmation of diagnoses was estimated to be 
£240,641. This translates to £6.81, £5,469 and £12,665 per individual  
screened, newly diagnosed and treated at the study centre, respectively.  
Base case results are presented in Table 2 and compare a screening and 
treatment strategy to a no screening and no treatment strategy. These results 
were based on the 19 patients who were treated with IFN/RBV following  
screening at the study centre. When comparing treatment versus no 
treatment, the cost offsets associated with avoided HCV-related complications 
provide a relative cost-saving in patients with HCV genotypes 1, 2 and 3. 
Patients with genotype 4 infection incurred a greater cost, due to the relatively 
low observed rate of SVR, but remained cost-effective with an incremental 
cost-effectiveness ratio (ICER) of £4,054 per QALY gained. Across all treated 
patients, treatment is dominant over no treatment; that is treatment provides 
greater health benefits at a lower overall cost. 
14 
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treatment strategy. However, when compared to the improvement in QALYs 
achieved in treated patients, the associated ICER of £2,400 (approximately 
€3,072/$3,840 USD) remains well below the accepted thresholds. Based 
upon screening this population of 35,355 women, it was estimated that the 
cost associated with screening each individual could be increased up to 
£31.04 and still remain cost-effective at the £20,000/QALY gained threshold. 
Table 2 demonstrates the potential impact of DAA use upon the cost-
effectiveness of a HCV screening programme. Whilst incurring increased 
therapy-related costs, the improved SVR rates associated with SOF+IFN/RBV 
generated significant increases in QALYs and life expectancy (DAA scenario 
1). A similar relationship was observed when IFN/RBV treatment failure was 
followed by SOF+IFN/RBV treatment (DAA scenario 2). These scenarios 
resulted in ICERs of £9,139 (approximately €11,697/$14,622) and £3,105 
(approximately €3,974/$4,968) respectively. 
Sensitivity analysis 
The screening strategy remained cost-effective under all sensitivity analyses 
performed, as presented in Table 3. The cost-effectiveness of screening was 
most significantly impacted by the prevalence of HCV infection amongst the 
screened women and the proportion of identified women treated. Compared 
to a screening cost threshold of approximately £31/person in the base case, 
varying the underlying HCV prevalence to 0.1% and 0.6% lead to thresholds 
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of £14.07 and £84.43, respectively. The most cost-effective measure is 
expected to be ensuring the treatment of all diagnosed viraemic patients. 
Results suggest that treating all identified patients within the screening 
programme would have been dominant over no screening. Furthermore, after 
adjusting the prevalence of HCV infection to 0.1% or 0.6%, treatment of all 
positively diagnosed women would remain a more cost-effective scenario than 
treating a proportion as in the base case. 
Conversely, age and changes in SVR were less influential. Increasing the age 
at which patients were diagnosed, however, proved to decrease cost-
effectiveness of the screening programme. Utilising alternative SVR rates had 
a minor impact on the cost-effectiveness of screening, increasing the 
estimated ICER to £3,922. A summary of ICER and screening cost threshold 
results are presented in Figure 3, where the dashed line represents the 
estimated cost per person screened incurred at the study centre. 
Additional analyses were undertaken relating to the most influential 
parameters for cost-effectiveness; i.e., the prevalence of HCV viraemia 
amongst the screened population and the uptake of treatment amongst those 
positively diagnosed. In each case, base case parameter values were utilised, 
whilst the prevalence of HCV or the rates of treatment uptake were contrasted 
over sensible ranges to investigate the effect upon cost-effectiveness. Results 
are presented in Figure 4, where the solid black line represents the 
£20,000/QALY threshold and the dashed black line represents the base case 
ICER of £2,400. 
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Discussion 
Within the population of this study, addition of HCV screening and treatment 
was expected to be cost-effective. These findings are driven by the relatively  
low additional costs required to implement HCV antibody testing alongside  
existing antenatal screening tests. Overall, the incidence of newly diagnosed  
HCV was 0.12%, whilst seemingly low, it is comparable to the prevalence of 
new HBV (0.16%) and HIV (0.04%) diagnoses observed amongst antenatal  
screenings in England in 2013 [35]. This study has demonstrated that cost-
effectiveness improves when the prevalence of HCV is increased assuming  
that costs and treatment uptake are comparable to those observed in this  
study. In countries, such as Egypt where antenatal HCV prevalence have  
been reported at up to 2.4% [36], the benefits of screening would potentially  
outweigh the additional cost incurred if the same assumptions were made.  
Furthermore, within that particular cohort, 90% of viraemic mothers were  
previously unaware of their infection and over 10% of infected patients would  
have been missed when undertaking screening based upon identification of 
risk factors. This supports the rationale for universal antenatal screening of 
HCV, akin to HBV and HIV. It provides the mother an opportunity to access  
treatment with a view of achieving SVR. At the time of writing, 22 of 44 newly  
diagnosed women are in position to have future pregnancies without risk of 
vertical transmission.  
Amongst patients considered in the analysis, the observed effectiveness of 
conventional interferon-based dual therapy in the antenatal population with  
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HCV genotypes 1–3 compared favourably to historical data. However,  
sensitivity analyses showed cost-effectiveness results were robust to  
deviations from the observed SVR rates. Since the analysis in this study was  
undertaken, an additional three patients were treated and achieved SVR: one  
was treated with IFN/RBV and boceprevir for 28 weeks and two further 
patients were treated with interferon-free DAA regimens as part of clinical  
trials; potentially resulting in an underestimation of cost-effectiveness. The  
costs of identification and treatment of these chronically infected women were  
shown to be offset by the reduced risk of future sequelae of HCV-related  
disease. Women, and their children, who may have been identified at a later 
stage are more likely to be symptomatic, more difficult to treat and at  
increased risk of developing complications and incurring higher costs.  
Improved cost-effectiveness estimated in younger patients further highlights  
the importance of early detection. Consideration of societal costs or costs  
incurred by patients, such as lost productivity were not accounted for,  
potentially underestimating the benefits of this screening programme.  
Screening strategies are receiving increasing emphasis, given the associated  
morbidity associated with HCV and the emergence of more efficacious 
treatments. Other focussed strategies, such as birth cohort screening, have 
been demonstrated to be cost-effective and have been implemented in the US  
to augment screening strategies in high risk patients [17]. This strategy offers 
screening to all Americans born between 1945 and 1965, a birth cohort that is 
estimated to contain 75% of unidentified HCV infected persons [5]; however,  
uptake rates for this programme have not yet been reported. Risk-based  
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screening strategies will inevitably miss cases, and by design the birth cohort-
screening programme in the US is likely not to capture 25% of HCV infections.  
Antenatal screening may offer a highly cost-effective strategy to identify HCV 
infection amongst a population that is most likely to benefit from treatment,  
due to demonstrated high rates of efficacy and therapy adherence.  
Urbanus et al. reported that screening for HCV in Amsterdam’s antenatal 
population was not cost-effective [21]. Two aspects that differ between the 
Urbanus study and this study, are (a) the inclusion of relatively high costs 
associated with screening and treatment within the Dutch population, and (b) 
the inclusion of life-years within the ICER calculation rather than QALYs. 
Indeed, when sensitivity analyses were performed with lower treatment costs, 
the Dutch screening programme was shown to be cost-effective, at a 
threshold of €20,000/QALY gained. The derivation of ICERs utilising life-years 
underestimates the benefit of treatment in relation to improved quality of life. 
This study demonstrated that antenatal screening has the potential to provide 
morbidity benefits as a result of detecting HCV-infected women earlier than 
they would normally be and thus preventing complications of HCV in later life. 
This study is subject to a number of limitations relating to both modelling  
assumptions and the underlying characteristics of the study centre and  
population. The study centre is based in London, and, as demonstrated in the 
patient demographics, may have an overrepresented migrant population.  
Further cost may be incurred to provide a comparable programme, although  
centres undertaking routine antenatal HBV screening will undoubtedly have 
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established infrastructure that would minimise costs of incorporating new HCV 
diagnoses too. When considering base case assumptions, it was estimated  
that an additional £856,890 could have been spent within this programme 
whilst maintaining cost-effectiveness at a threshold of £20,000 per QALY,  
when using base case assumptions.  
Application of UK rates of alcohol consumption, in the absence of study-
specific data, may have affected the derivation of fibrosis stage transition  
rates; however, this is unlikely to have made any significant difference to 
modelling results. Additionally, age-dependent health utility estimates were 
not considered within the modelling analysis; however, when considering the 
young age of the modelled cohort compared to the average UK HCV patient,  
and that health state utility estimates are representative of patients of differing  
ages, such an assumption is not likely to introduce significant bias. Given the 
relatively high rate of HCV antibody positive but PCR negative patients within  
our study population, 58 of 35,355 women (0.16%) would have experienced a 
brief negative impact on quality of life until their spontaneously cleared status 
was confirmed. Mothers that were given a new positive diagnosis in the 
antenatal period but were not offered treatment may also incur a decrement in  
quality of life. We suggest, however, that the overall gain associated with early 
diagnosis and improved treatment outcomes is likely to outweigh this. The 
assumption that in the absence of screening women would not be otherwise 
diagnosed or treated until symptomatic may lead to overestimations of the 
benefit of screening; however, given that the majority of identified patients 
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would likely not be screened due to their “low” risk status, and in the absence 
of additional supporting data, this is an appropriate assumption.  
The study did not evaluate the costs or benefits of the testing and treatment of 
children perinatally exposed. Three vertical transmissions from 44 newly 
diagnosed mothers were observed. There is little information available relating  
to the modelling of perinatally acquired HCV.  Contact cases were not 
incorporated within the analysis, as the patient records could not be reliably 
used to assess contact tracing and treatment outcomes. Whilst not 
considered from an economic point of view, the detection of these cases has 
potentially allowed for appropriate and timely management preventing further 
morbidity and possibly further transmission. 
To date, HCV screening is reserved for individuals with elevated risks of 
infection, such as injecting drug use and presence of other blood borne 
viruses. Despite higher prevalence rates in such groups treatment uptake is 
suboptimal and is of limited cost efficiency [37][38][39]. Due to complex social 
factors eight mothers did not attend clinic follow up and thus did not undertake 
treatment. This highlights an area in which service development can be 
optimised further. 
Antenatal screening policies for HCV require reconsideration, given the 
positive outcomes following identification of infected women at an early stage 
of their disease. This study shows that, despite increased treatment costs of 
DAAs, associated improvements in SVR rates are expected to make their 
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inclusion in antenatal screening and treatment strategies cost-effective. The 
improved tolerability and shorter duration of newer HCV regimens may also 
further increase the uptake of therapy following diagnosis of HCV. It is hoped 
that committees responsible for national antenatal screening programmes will 
re-evaluate the need for HCV screening in the light of the evidence provided 
by this study. 
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Figure 1: Flow diagram of the MONARCH model. Annual transition 
probabilities control progression through disease states. 
Table 1: Cost and health utility parameters 
Figure 2: Flow diagram showing the results of the numbers tested and the 
number of new diagnoses of HCV based on antenatal screening and 
outcomes of treatment within the cohort. 
Table 2: Base case (BC) cost-effectiveness results (per treated patient) 
Figure 3: Incremental cost-effectiveness ratios and estimated maximum cost 
per patient screened, assuming a maximum cost-effectiveness threshold of 
£20,000/QALY. The dashed line represents the estimated cost per person  
screened incurred at the study centre  
Figure 4: The relationship between the cost-effectiveness of screening: and 
the prevalence of HCV amongst screened patients; and the treatment uptake 
amongst those newly identified as HCV positive. The solid black line  
represents the £20,000/QALY threshold and the dashed black line represents 
the base case ICER of £2,400.  
Table 3: Sensitivity analysis results (per treated patient) 
Table S1: Annual disease progression rates, distribution types and 
parameters used in the model 
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Table S2: Unit costs and resource use of screening cost components 
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Table 1 
      
 
Mean 
Cost parameters 
SE Source Mean 
Health utility parameters 
SE Source 
Disease State (annual)       
F0/F1 £177.47 £35.01  0.77 0.015  
F2/F3 £922.08 £97.82  0.66 0.031  
F4 £1,463.50 £297.45  0.55 0.054  
DC £11,728.61 £1,954.09  0.45 0.031  
HCC 
LTx (Year 1) 
£10,451.58 
£47,310.55 
£2,456.09 
£6,843.48 
[28]  
0.45 
0.45 
0.031 
0.031 
[30] 
LTx (Year 2+) £1,781.15 £456.57  0.67 0.066  
SVR from F0/F1 £333.08 £62.05  0.82 0.043  
SVR from F2/F3 £922.08 £97.74  0.72 0.048  
SVR from F4 £1,463.50 £288.07  0.72 0.048  
Treatments       
IFN/RBV £191.35/week NA  0.109* 0.010 [33] 
SOF+IFN/RBV £1,519.81/week NA [29]  0.148* 0.010 [34] 
 
*These values represent therapy-specific disutilities. 
DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN/RBV, 
pegylated interferon α and ribavirin; LTx, liver transplant; RNA, ribonucleic acid; SOF, sofosbuvir; SVR, 
sustained virologic respons 
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Table 2 
 DAA scenario 1: Base case: 
All 
IFN/RBV 
SOF+IFN/RBV 
DAA scenario 2: 
SOF+IFN/RBV in 
IFN/RBV failures 
No treatment    
Total cost (£) 20,749 20,749 20,749 
Total QALYs 15.39 15.39 15.39 
Total life years 22.13 22.13 22.13 
Treatment    
Total cost (£) 14,233 38,630 18,723 
Total QALYs 17.95 18.73 18.82 
Total life years 23.07 23.33 23.37 
Cost-effectiveness results of treatment versus no treatment  
Δ Cost (£) -6,516 17,881 -2,027 
Δ QALY 2.56 3.34 3.43 
Δ Life years 0.94 1.19 1.24 
ICER (£/QALY) Dominant £5,350 Dominant 
Cost-effectiveness of screening programme   
Δ Cost (£) 6,149 30,546 10,639 
Δ QALY 2.56 3.34 3.43 
ICER (£/QALY) 2,400 9,139 3,105 
Maximum cost of screening program to remain cost-effective at £20,000/QALY 
(£)    
Total 1,097,531 930,390 1,340,402 
Per screening 31.04 26.32 37.91 
 
DAA, direct acting antiviral, ICER, incremental cost-effectiveness ratio; IFN/RBV, pegylated interferon α 
and ribavirin; QALY, quality-adjusted life year; SOF, sofosbuvir. 
  
Table 3 
Table 3 
 
Lifetime cost-
effectiveness 
Base 
case (BC) 
SA 1a: SA 1b: SA 2: SA 3: SA 4a: 0.1% HCV SA 4b: 0.6% HCV 
Age 28 Age 38 Historical 
SVR % Treat all Treat BC % Treat all Treat BC % Treat all 
No treatment 
Total cost (£) 20,749 21,440 19,840 21,749 20,837 20,749 20,837 20,749 20,837 
Total QALYs 15.39 15.90 14.80 15.39 15.38 15.39 15.38 15.39 15.38 
Total life years 22.13 22.89 21.25 22.13 22.13 22.13 22.13 22.13 22.13 
Treatment 
Total cost (£) 14,233 14,417 13,993 16,604 14,152 14,233 14,152 14,233 14,152 
Total QALYs 17.95 18.63 17.17 17.56 17.96 17.95 17.96 17.95 17.96 
Total life years 23.07 23.95 22.06 22.92 23.08 23.07 23.08 23.07 23.08 
Cost-effectiveness of treatment versus no treatment 
Δ Cost (£) -6,516 -7,024 -5,847 -4,146 -6,685 -6,516 -6,685 -6,516 -6,685 
Δ QALY 2.56 2.73 2.37 2.17 2.59 2.56 2.59 2.56 2.59 
Δ Life years 0.94 1.05 0.81 0.79 0.95 0.94 0.95 0.94 0.95 
ICER (£/QALY) Dominant Dominant Dominant Dominant Dominant Dominant Dominant Dominant Dominant 
Cost-effectiveness of screening programme 
Δ Cost (£) 6,149 5,642 6,818 8,520 -1,216 19,198 4,419 -124 -3,925 
Δ QALY 2.56 2.73 2.37 2.17 2.59 2.56 2.59 2.56 2.59 
ICER (£/QALY) 2,400 2,065 2,881 3,922 Dominant 7,492 1,707 Dominant Dominant 
Maximum cost of screening to remain cost-effective at £20,000/QALY (£) 
Total 1,097,531 1,171,480 1,010,514 904,304 2,572,019 497,477 1,165,817 2,984,863 6,994,903 
Per patient 31.04 33.13 28.58 25.58 72.75 14.07 32.97 84.43 197.85
  
Figure 1 
 
Figure 1 
 
  
Figure 2 
 
 
Patients screened: 
35,355 
*During the manuscript review phase an additional three patients were treated, two of whom achieved SVR 
through use of unlicensed therapies and one through the use of boceprevir combined with IFN/RBV. These 
patients have not been incorporated within the analysis. 
 
HCV antibody positive: 
136 
 
HCV RNA positive: 
60 
HCV antibody negative: 
35,219 
 
HCV RNA negative: 
76 
 
Achieved SVR: 7 2 4 1 0 
Treated with 
IFN/RBV* 9 2 5 3 0 
F0-F1 
F2-F3 
Unknown 
Total: 21 4 11 6 2 
Genotype 1 Genotype 2 Genotype 3 Genotype 4 Unknown 
5 
2 
14 
0 
2 
2 
4
 
1
 
6 
4 
0 
2 0 
0 
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New diagnoses: 
44 
 
Prior diagnoses: 
16 
 
Previously 
treated: 
18 
 
Spontaneous 
clearance: 
58 
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